<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02020408</url>
  </required_header>
  <id_info>
    <org_study_id>090661</org_study_id>
    <secondary_id>R01MH092793</secondary_id>
    <nct_id>NCT02020408</nct_id>
  </id_info>
  <brief_title>Monoamine Contributions to Neurocircuitry in Eating Disorders</brief_title>
  <official_title>Monoamine Contributions to Neurocircuitry in Eating Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will use brain imaging technologies to measure several neurotransmitters
      (serotonin and dopamine) that contribute to our abilities to respond to reward or inhibit our
      impulses, and which are known to be altered in the brain of people with anorexia nervosa (AN)
      and bulimia nervosa (BN). Because palatable food stimulates dopamine secretion, we propose to
      use a challenge with brain imaging that will stimulate dopamine release which we hypothesize
      will generate anxiety rather than pleasure in AN, and will help explain why AN restrict
      eating in order to reduce anxiety. This study will help to understand the unique puzzling
      symptoms in eating disorders and contribute to finding better methods for identifying
      effective treatments for these often relapsing and sometimes chronic disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alterations of serotonin (5-HT) and dopamine (DA) activity may contribute to extremes of
      appetitive behaviours in anorexia nervosa (AN) and bulimia nervosa (BN), through effects on
      inhibitory and reward neural pathways. To avoid the confounding effects of malnutrition, and
      because they have behaviours and neural circuit alterations relevant for this study, we will
      study 25 recovered (REC) restricting-type AN, 25 REC bulimic-type AN (AN-BN), 25 REC BN, and
      25 control women (CW). This 5 year study, of women 18 to 45 years old, will employ positron
      emission tomography (PET) imaging with radioligands for the 5-HT transporter ([11C]DASB) and
      DA D2/D3 receptors ([11C]raclopride).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-HT Transporter Binding as Measured During the PET Scan</measure>
    <time_frame>90 minute PET scan</time_frame>
    <description>Use PET and [11C]DASB to explore 5-HTT receptor binding potential midbrain and striatal regions of interest in eating disorder subtypes.
The Binding Potential (BP) was calculated as BP Non Displaceable (ND) = (VT/VND) −1. [VT = distribution volume in tissue; VND = non-displaceable distribution volume]. The binding of the 5-HTT on PET presumably reflects 5-HTT density and/or affinity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dopamine D2/D3 Receptor Binding as Measured During the PET Scan After Amphetamine Administration</measure>
    <time_frame>90 min PET scan</time_frame>
    <description>Use PET and [11C]raclopride to explore Dopamine D2/D3 receptor binding potential (BPND) in striatal regions of interest in eating disorder subtypes after amphetamine administration. The Binding Potential (BP) was calculated as BP Non Displaceable (ND) = (VT/VND) −1. [VT = distribution volume in tissue; VND = non-displaceable distribution volume].</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Eating Disorder</condition>
  <arm_group>
    <arm_group_label>[11C]raclopride, [11C]DASB, amphetamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One time administration of oral amphetamine based on subject's weight (0.5 mg/kg). One PET scan using [11C]DASB. Two PET scans using [11C]raclopride.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[11C]raclopride</intervention_name>
    <description>1.[11C]raclopride -The change (Δ) in BPND (the difference between the [11C]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND</description>
    <arm_group_label>[11C]raclopride, [11C]DASB, amphetamine</arm_group_label>
    <other_name>Raclopride, serial number 009</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[11C]DASB</intervention_name>
    <description>BPND of [11C]DASB.</description>
    <arm_group_label>[11C]raclopride, [11C]DASB, amphetamine</arm_group_label>
    <other_name>DASB, serial number 0011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amphetamine</intervention_name>
    <description>The change (Δ) in BPND (the difference between the [11C]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND.</description>
    <arm_group_label>[11C]raclopride, [11C]DASB, amphetamine</arm_group_label>
    <other_name>dextroamphetamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion

          -  history of Diagnostic and Statistical Manual (DSM-IV) diagnosis of anorexia or
             bulimia.

          -  AN women have history of average body weight (ABW) below 85% for height.

          -  AN-BN subjects have history of ABW below 85% ABW.

          -  AN-BN subjects have history of binging/purging behaviors during a period of low
             weight.

          -  Subjects must be right-handed.

          -  Subjects have been recovered for 12 months or more.

        Exclusion

          -  Diagnosis of alcohol or drug abuse or dependence in the 3 months.

          -  Alcohol or substance use within 30 days.

          -  Current diagnosis of an Axis I disorder.

          -  Organic brain syndromes, dementia, psychotic disorders, or mental retardation.

          -  Neurological or medical disorders such as seizure disorder, renal disease, diabetes,
             thyroid disease, EKG indicative of electrolyte imbalance

          -  BN subjects whose purging methods were the use of laxatives, diuretics

          -  Use of psychoactive medication in the 3 months.

          -  Pregnancy or lactation.

          -  Tobacco use in the 3 months.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Kaye, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ursula Bailer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 11, 2013</study_first_submitted>
  <study_first_submitted_qc>December 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2013</study_first_posted>
  <results_first_submitted>July 10, 2019</results_first_submitted>
  <results_first_submitted_qc>April 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 27, 2020</results_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Walter Kaye</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Feeding and Eating Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raclopride</mesh_term>
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 9, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT02020408/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>[11C]Raclopride, [11C]DASB, Amphetamine</title>
          <description>healthy control women (CW);
women recovered from restricting type anorexia nervosa (REC AN);
women recovered from bulimic type anorexia nervosa (REC AN-BN)
women recovered from from bulimia nervosa (REC BN)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>According to the study protocol and inclusion criteria all participants needed to be female, between age 18 and 65 and were enrolled in the US.</population>
      <group_list>
        <group group_id="B1">
          <title>[11C]Raclopride, [11C]DASB, Amphetamine</title>
          <description>healthy control women (CW);
women recovered from restricting type anorexia nervosa (REC AN);
women recovered from bulimic type anorexia nervosa (REC AN-BN)
women recovered from from bulimia nervosa (REC BN)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>5-HT Transporter Binding as Measured During the PET Scan</title>
        <description>Use PET and [11C]DASB to explore 5-HTT receptor binding potential midbrain and striatal regions of interest in eating disorder subtypes.
The Binding Potential (BP) was calculated as BP Non Displaceable (ND) = (VT/VND) −1. [VT = distribution volume in tissue; VND = non-displaceable distribution volume]. The binding of the 5-HTT on PET presumably reflects 5-HTT density and/or affinity.</description>
        <time_frame>90 minute PET scan</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[11C]DASB Binding Potential Control Women</title>
            <description>[11C] DASB Binding potential (BPND) in control women (healthy controls)</description>
          </group>
          <group group_id="O2">
            <title>[11C]DASB Binding Potential in REC AN</title>
            <description>[11C]DASB binding potential in women recovered from restricting type anorexia nervosa (REC AN)</description>
          </group>
          <group group_id="O3">
            <title>[11C]DASB Binding Potential in REC ANBN</title>
            <description>[11C]DASB binding potential in women recovered from bulimic type anorexia nervosa (REC AN-BN)</description>
          </group>
          <group group_id="O4">
            <title>[11C]DASB Binding Potential in REC BN</title>
            <description>[11C]DASB binding potential in women recovered from bulimia nervosa (REC BN)</description>
          </group>
        </group_list>
        <measure>
          <title>5-HT Transporter Binding as Measured During the PET Scan</title>
          <description>Use PET and [11C]DASB to explore 5-HTT receptor binding potential midbrain and striatal regions of interest in eating disorder subtypes.
The Binding Potential (BP) was calculated as BP Non Displaceable (ND) = (VT/VND) −1. [VT = distribution volume in tissue; VND = non-displaceable distribution volume]. The binding of the 5-HTT on PET presumably reflects 5-HTT density and/or affinity.</description>
          <units>binding potential (BPND)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>[11C]DASB BPND anteroventral striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="0.26"/>
                    <measurement group_id="O2" value="1.54" spread="0.32"/>
                    <measurement group_id="O3" value="1.46" spread="0.47"/>
                    <measurement group_id="O4" value="1.60" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>[11C]DASB BPND post dorsal caudate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.15"/>
                    <measurement group_id="O2" value="0.35" spread="0.18"/>
                    <measurement group_id="O3" value="0.39" spread="0.16"/>
                    <measurement group_id="O4" value="0.37" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>[11C]DASB BPND posterior putamen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="0.25"/>
                    <measurement group_id="O2" value="1.27" spread="0.18"/>
                    <measurement group_id="O3" value="1.17" spread="0.39"/>
                    <measurement group_id="O4" value="1.32" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>[11C]DASB BPND predorsal caudate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.19"/>
                    <measurement group_id="O2" value="0.99" spread="0.32"/>
                    <measurement group_id="O3" value="0.99" spread="0.34"/>
                    <measurement group_id="O4" value="0.98" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>[11C]DASB BPND anterior putamen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="0.26"/>
                    <measurement group_id="O2" value="1.59" spread="0.26"/>
                    <measurement group_id="O3" value="1.49" spread="0.48"/>
                    <measurement group_id="O4" value="1.57" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>[11C]DASB BPND midbrain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="0.31"/>
                    <measurement group_id="O2" value="2.06" spread="0.30"/>
                    <measurement group_id="O3" value="1.98" spread="0.60"/>
                    <measurement group_id="O4" value="2.17" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt; 0.05</p_value>
            <p_value_desc>The p value was calculated and adjusted for multiple comparisons (Bonferroni).</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dopamine D2/D3 Receptor Binding as Measured During the PET Scan After Amphetamine Administration</title>
        <description>Use PET and [11C]raclopride to explore Dopamine D2/D3 receptor binding potential (BPND) in striatal regions of interest in eating disorder subtypes after amphetamine administration. The Binding Potential (BP) was calculated as BP Non Displaceable (ND) = (VT/VND) −1. [VT = distribution volume in tissue; VND = non-displaceable distribution volume].</description>
        <time_frame>90 min PET scan</time_frame>
        <population>Due to technical problems and temporary closure of the PET Facility during the study and consequent lack of time and funding for additional scanning, we were unable to recruit a sufficient number of women recovered from bulimia nervosa (BN) for the AMPHETAMINE CHALLENGE STUDY and therefore no data for this outcome measure were collected in REC BN.</population>
        <group_list>
          <group group_id="O1">
            <title>[11C]Raclopride Binding Potential Control Women</title>
            <description>[11C]raclopride binding potential in control women after amphetamine administration</description>
          </group>
          <group group_id="O2">
            <title>[11C]Raclopride Binding Potential in REC AN</title>
            <description>[11C]raclopride binding potential in women recovered from restricting type anorexia nervosa (REC AN) after amphetamine administration</description>
          </group>
          <group group_id="O3">
            <title>[11C]Raclopride Binding Potential in REC ANBN</title>
            <description>[11C]raclopride binding potential in womenrecovered from bulimic type anorexia nervosa (REC ANBN) after amphetamine administration</description>
          </group>
        </group_list>
        <measure>
          <title>Dopamine D2/D3 Receptor Binding as Measured During the PET Scan After Amphetamine Administration</title>
          <description>Use PET and [11C]raclopride to explore Dopamine D2/D3 receptor binding potential (BPND) in striatal regions of interest in eating disorder subtypes after amphetamine administration. The Binding Potential (BP) was calculated as BP Non Displaceable (ND) = (VT/VND) −1. [VT = distribution volume in tissue; VND = non-displaceable distribution volume].</description>
          <population>Due to technical problems and temporary closure of the PET Facility during the study and consequent lack of time and funding for additional scanning, we were unable to recruit a sufficient number of women recovered from bulimia nervosa (BN) for the AMPHETAMINE CHALLENGE STUDY and therefore no data for this outcome measure were collected in REC BN.</population>
          <units>binding potential (BPND)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>[11C]raclopride BPND anteroventral striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" spread="0.22"/>
                    <measurement group_id="O2" value="2.01" spread="0.15"/>
                    <measurement group_id="O3" value="1.94" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>[11C]raclopride BPND post dorsal caudate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.27"/>
                    <measurement group_id="O2" value="1.62" spread="0.19"/>
                    <measurement group_id="O3" value="1.69" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>[11C]raclopride BPND anterior putamen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.71" spread="0.26"/>
                    <measurement group_id="O2" value="2.65" spread="0.22"/>
                    <measurement group_id="O3" value="2.60" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>[11C]raclopride BPND posterior putamen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53" spread="0.32"/>
                    <measurement group_id="O2" value="2.46" spread="0.26"/>
                    <measurement group_id="O3" value="2.47" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>[11C]raclopride BPND predorsal caudate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" spread="0.30"/>
                    <measurement group_id="O2" value="2.40" spread="0.14"/>
                    <measurement group_id="O3" value="2.47" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A General Linear Model using log([11C]raclopride BPND) after amphetamine administration as dependent variable and Diagnostic Group as independent variable was used. Baseline (before amphetamine administration) [11C]raclopride BPND was used as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>The p value was calculated and adjusted for multiple comparisons (Bonferroni).</p_value_desc>
            <method>General Linear Model</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>[11C]Raclopride, [11C]DASB, Amphetamine</title>
          <description>healthy control women (CW);
women recovered from restricting type anorexia nervosa (REC AN);
women recovered from bulimic type anorexia nervosa (REC AN-BN)
women recovered from from bulimia nervosa (REC BN)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>High blood pressure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Walter H. Kaye, MD</name_or_title>
      <organization>UCSD Department of Psychiatry</organization>
      <phone>858-534 ext 8019</phone>
      <email>wkaye@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

